1.5 KiB
Executable file
https://pubmed.ncbi.nlm.nih.gov/32113648/
"Genetic evidence fails to support a cardioprotective role for apoA-I. This is in line with the cumulative evidence showing that HDL-related phenotypes are unlikely to have a protective role in CAD."
https://pubmed.ncbi.nlm.nih.gov/28847206/
"Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo."
https://pubmed.ncbi.nlm.nih.gov/17984165/
"Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition."
https://pubmed.ncbi.nlm.nih.gov/23126252/
"In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events."
https://pubmed.ncbi.nlm.nih.gov/28514624/
"Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease."
https://pubmed.ncbi.nlm.nih.gov/32203549/
#disease #HDL #HDLp #LDL #coronary_heart_disease #cardiovascular_disease #CETP_inhibitors #ApoA1 #blood_lipids #CETP_inhibitors #lipidology